Symbols / CRIS
CRIS Chart
About
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 14.79M |
| Enterprise Value | 35.51M | Income | -36.56M | Sales | 11.65M |
| Book/sh | -1.15 | Cash/sh | 0.70 | Dividend Yield | — |
| Payout | 0.00% | Employees | 34 | IPO | — |
| P/E | — | Forward P/E | -0.69 | PEG | — |
| P/S | 1.27 | P/B | -0.94 | P/C | — |
| EV/EBITDA | -1.04 | EV/Sales | 3.05 | Quick Ratio | 0.62 |
| Current Ratio | 0.70 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -3.30 | EPS next Y | -1.57 | EPS Growth | — |
| Revenue Growth | 8.40% | Earnings | 2026-02-27 | ROA | -61.20% |
| ROE | — | ROIC | — | Gross Margin | -172.15% |
| Oper. Margin | -218.01% | Profit Margin | 0.00% | Shs Outstand | 13.69M |
| Shs Float | 10.93M | Short Float | 4.64% | Short Ratio | 0.54 |
| Short Interest | — | 52W High | 3.18 | 52W Low | 0.77 |
| Beta | 3.07 | Avg Volume | 507.79K | Volume | 104.10K |
| Target Price | $14.00 | Recom | None | Prev Close | $1.09 |
| Price | $1.08 | Change | -0.92% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$14.00
Mean price target
2. Current target
$1.08
Latest analyst target
3. DCF / Fair value
$-22.81
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.08
Low
$5.00
High
$20.00
Mean
$14.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-03-31 | main | HC Wainwright & Co. | Buy → Buy | $16 |
| 2024-12-10 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-11-01 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-08-01 | reit | HC Wainwright & Co. | Buy → Buy | $26 |
| 2024-05-15 | main | Truist Securities | Buy → Buy | $26 |
| 2024-05-15 | reit | HC Wainwright & Co. | Buy → Buy | $26 |
| 2024-05-15 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-05-08 | reit | HC Wainwright & Co. | Buy → Buy | $26 |
| 2024-02-09 | main | HC Wainwright & Co. | Buy → Buy | $26 |
| 2023-11-17 | init | Truist Securities | — → Buy | $26 |
- Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds - PR Newswire Wed, 07 Jan 2026 08
- Analysts Have Been Trimming Their Curis, Inc. (NASDAQ:CRIS) Price Target After Its Latest Report - Yahoo Finance Sun, 09 Nov 2025 08
- Curis Regains Nasdaq Compliance, Remains Under Monitoring Period - The Globe and Mail ue, 10 Feb 2026 08
- Curis (CRIS) Moves to Offer Over 107 Million Shares of Common St - GuruFocus Fri, 13 Feb 2026 22
- Curis, Inc. (NASDAQ:CRIS) Just Reported, And Analysts Assigned A US$16.33 Price Target - simplywall.st Fri, 08 Aug 2025 07
- Curis stock soars after securing $80.8 million private placement deal - Investing.com Wed, 07 Jan 2026 08
- Cris-Tim Family Holding announces initial public offering (IPO) between October 17 and 29, 2025 - Business Review Mon, 20 Oct 2025 07
- Curis Announces $7.0 Million Registered Direct and Concurrent Private Placement - PR Newswire Wed, 02 Jul 2025 07
- Curis (CRIS) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance ue, 05 Aug 2025 07
- Why Investors Shouldn't Be Surprised By Curis, Inc.'s (NASDAQ:CRIS) 27% Share Price Plunge - simplywall.st Sun, 04 Jan 2026 08
- Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PR Newswire Fri, 03 Oct 2025 07
- Curis Cancer Drug Shows 69% Success Rate, FDA Accelerated Approval Path Emerges - Stock Titan Mon, 31 Mar 2025 07
- Cris-Tim Family Holding announces plan to launch IPO on the Bucharest Stock Exchange - Business Review Mon, 29 Sep 2025 07
- Curis Granted Nasdaq Compliance Extension Until November - TipRanks Fri, 24 Oct 2025 07
- Curis Inc (CRIS) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance Mon, 04 Aug 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -42.57M | -45.14M | -51.67M | -40.81M |
| TotalUnusualItems | 0.00 | |||
| TotalUnusualItemsExcludingGoodwill | 0.00 | |||
| NetIncomeFromContinuingOperationNetMinorityInterest | -43.39M | -47.41M | -56.67M | -45.44M |
| ReconciledDepreciation | 203.00K | 255.00K | 233.00K | 158.00K |
| ReconciledCostOfRevenue | 98.00K | 212.00K | 257.00K | 533.00K |
| EBITDA | -42.57M | -45.14M | -51.67M | -40.81M |
| EBIT | -42.77M | -45.39M | -51.90M | -40.96M |
| NetInterestIncome | 1.15M | 919.00K | -3.65M | -4.26M |
| InterestExpense | 615.00K | 2.02M | 4.77M | 4.47M |
| InterestIncome | 1.77M | 2.94M | 1.12M | 211.00K |
| NormalizedIncome | -43.39M | -47.41M | -56.67M | -45.44M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -43.39M | -47.41M | -56.67M | -45.44M |
| TotalExpenses | 55.45M | 58.35M | 63.18M | 52.71M |
| RentExpenseSupplemental | 617.00K | |||
| TotalOperatingIncomeAsReported | -44.54M | -48.33M | -53.02M | -42.06M |
| DilutedAverageShares | 6.31M | 5.29M | 4.67M | 4.58M |
| BasicAverageShares | 6.31M | 5.29M | 4.67M | 4.58M |
| DilutedEPS | -6.88 | -8.96 | -12.20 | -10.00 |
| BasicEPS | -6.88 | -8.96 | -12.20 | -10.00 |
| DilutedNIAvailtoComStockholders | -43.39M | -47.41M | -56.67M | -45.44M |
| NetIncomeCommonStockholders | -43.39M | -47.41M | -56.67M | -45.44M |
| NetIncome | -43.39M | -47.41M | -56.67M | -45.44M |
| NetIncomeIncludingNoncontrollingInterests | -43.39M | -47.41M | -56.67M | -45.44M |
| NetIncomeContinuousOperations | -43.39M | -47.41M | -56.67M | -45.44M |
| PretaxIncome | -43.39M | -47.41M | -56.67M | -45.44M |
| OtherIncomeExpense | 890.00K | |||
| OtherNonOperatingIncomeExpenses | 890.00K | |||
| SpecialIncomeCharges | 0.00 | |||
| NetNonOperatingInterestIncomeExpense | 1.15M | 919.00K | -3.65M | -4.26M |
| InterestExpenseNonOperating | 615.00K | 2.02M | 4.77M | 4.47M |
| InterestIncomeNonOperating | 1.77M | 2.94M | 1.12M | 211.00K |
| OperatingIncome | -44.54M | -48.33M | -53.02M | -42.06M |
| OperatingExpense | 55.35M | 58.14M | 62.92M | 52.18M |
| ResearchAndDevelopment | 38.56M | 39.50M | 43.28M | 34.88M |
| SellingGeneralAndAdministration | 16.79M | 18.65M | 19.65M | 17.30M |
| GeneralAndAdministrativeExpense | 16.79M | 18.65M | 19.65M | 17.30M |
| OtherGandA | 7.16M | 8.41M | 7.84M | 7.26M |
| InsuranceAndClaims | 904.00K | 1.07M | 1.41M | 1.02M |
| RentAndLandingFees | 617.00K | |||
| SalariesAndWages | 8.72M | 9.17M | 10.40M | 9.01M |
| GrossProfit | 10.81M | 9.81M | 9.90M | 10.12M |
| CostOfRevenue | 98.00K | 212.00K | 257.00K | 533.00K |
| TotalRevenue | 10.91M | 10.02M | 10.16M | 10.65M |
| OperatingRevenue | 10.91M | 10.02M | 10.16M | 10.75M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 8.49M | 5.89M | 4.83M | 4.58M |
| ShareIssued | 8.49M | 5.89M | 4.83M | 4.58M |
| TotalDebt | 2.95M | 2.79M | 3.94M | 5.04M |
| TangibleBookValue | -14.98M | 10.69M | 37.57M | 81.72M |
| InvestedCapital | -6.00M | 19.67M | 46.55M | 90.71M |
| WorkingCapital | 7.36M | 38.89M | 82.11M | 108.94M |
| NetTangibleAssets | -14.98M | 10.69M | 37.57M | 81.72M |
| CapitalLeaseObligations | 2.95M | 2.79M | 3.94M | 5.04M |
| CommonStockEquity | -6.00M | 19.67M | 46.55M | 90.71M |
| TotalCapitalization | -6.00M | 19.67M | 46.55M | 90.71M |
| TotalEquityGrossMinorityInterest | -6.00M | 19.67M | 46.55M | 90.71M |
| StockholdersEquity | -6.00M | 19.67M | 46.55M | 90.71M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | 229.00K | -186.00K | -109.00K |
| OtherEquityAdjustments | 229.00K | -186.00K | -109.00K | |
| RetainedEarnings | -1.24B | -1.20B | -1.15B | -1.09B |
| AdditionalPaidInCapital | 1.23B | 1.22B | 1.20B | 1.18B |
| CapitalStock | 85.00K | 59.00K | 48.00K | 916.00K |
| CommonStock | 85.00K | 59.00K | 48.00K | 916.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 47.26M | 57.61M | 62.30M | 71.59M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 28.24M | 35.59M | 52.28M | 58.16M |
| OtherNonCurrentLiabilities | 26.62M | 34.10M | 49.48M | 53.80M |
| LongTermDebtAndCapitalLeaseObligation | 1.62M | 1.49M | 2.80M | 4.36M |
| LongTermCapitalLeaseObligation | 1.62M | 1.49M | 2.80M | 4.36M |
| CurrentLiabilities | 19.03M | 22.02M | 10.01M | 13.44M |
| OtherCurrentLiabilities | 7.56M | 8.50M | ||
| CurrentDebtAndCapitalLeaseObligation | 1.34M | 1.30M | 1.14M | 682.00K |
| CurrentCapitalLeaseObligation | 1.34M | 1.30M | 1.14M | 682.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 3.15M | 3.26M | ||
| PayablesAndAccruedExpenses | 10.13M | 12.21M | 8.87M | 9.50M |
| CurrentAccruedExpenses | 7.11M | 9.04M | 5.68M | 3.08M |
| Payables | 3.02M | 3.17M | 3.19M | 6.42M |
| AccountsPayable | 3.02M | 3.17M | 3.19M | 6.42M |
| TotalAssets | 41.27M | 77.28M | 108.85M | 162.30M |
| TotalNonCurrentAssets | 14.88M | 16.37M | 16.73M | 39.93M |
| OtherNonCurrentAssets | 2.50M | 3.90M | 2.66M | 726.00K |
| InvestmentsAndAdvances | 0.00 | 23.96M | ||
| GoodwillAndOtherIntangibleAssets | 8.98M | 8.98M | 8.98M | 8.98M |
| Goodwill | 8.98M | 8.98M | 8.98M | 8.98M |
| NetPPE | 3.39M | 3.49M | 5.09M | 6.25M |
| AccumulatedDepreciation | -1.01M | -1.99M | -2.46M | -2.23M |
| GrossPPE | 4.41M | 5.48M | 7.55M | 8.48M |
| Leases | 257.00K | 257.00K | 257.00K | 214.00K |
| OtherProperties | 3.16M | 3.06M | 4.40M | 5.75M |
| MachineryFurnitureEquipment | 987.00K | 2.17M | 2.89M | 2.52M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 26.39M | 60.91M | 92.12M | 122.38M |
| OtherCurrentAssets | 3.04M | 1.78M | 3.52M | 3.27M |
| PrepaidAssets | 3.27M | |||
| Receivables | 3.35M | 2.79M | 2.98M | 3.22M |
| AccountsReceivable | 3.35M | 2.79M | 2.98M | 3.22M |
| CashCashEquivalentsAndShortTermInvestments | 20.00M | 56.33M | 85.62M | 115.88M |
| OtherShortTermInvestments | 0.00 | 29.65M | 65.97M | 75.87M |
| CashAndCashEquivalents | 20.00M | 26.68M | 19.66M | 40.01M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -39.56M | -38.43M | -54.75M | -37.62M |
| RepaymentOfDebt | 0.00 | |||
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 12.02M | 14.12M | 5.84M | 0.00 |
| CapitalExpenditure | -416.00K | |||
| InterestPaidSupplementalData | 461.00K | 2.36M | 4.11M | 4.44M |
| EndCashPosition | 20.54M | 27.23M | 20.29M | 40.74M |
| BeginningCashPosition | 27.23M | 20.29M | 40.74M | 130.43M |
| ChangesInCash | -6.68M | 6.93M | -20.45M | -89.69M |
| FinancingCashFlow | 3.44M | 7.58M | 867.00K | -4.17M |
| CashFlowFromContinuingFinancingActivities | 3.44M | 7.58M | 867.00K | -4.17M |
| NetOtherFinancingCharges | -8.59M | -6.54M | -4.97M | -4.47M |
| ProceedsFromStockOptionExercised | 248.00K | 300.00K | ||
| NetCommonStockIssuance | 12.02M | 14.12M | 5.84M | 0.00 |
| CommonStockIssuance | 12.02M | 14.12M | 5.84M | 0.00 |
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtPayments | 0.00 | |||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | 29.44M | 37.79M | 33.02M | -47.90M |
| CashFlowFromContinuingInvestingActivities | 29.44M | 37.79M | 33.02M | -47.90M |
| NetInvestmentPurchaseAndSale | 29.44M | 37.79M | 33.44M | -47.90M |
| SaleOfInvestment | 47.54M | 108.13M | 95.44M | 45.23M |
| PurchaseOfInvestment | -18.10M | -70.34M | -62.00M | -93.12M |
| NetPPEPurchaseAndSale | 0.00 | -416.00K | 0.00 | |
| PurchaseOfPPE | 0.00 | -416.00K | 0.00 | |
| OperatingCashFlow | -39.56M | -38.43M | -54.34M | -37.62M |
| CashFlowFromContinuingOperatingActivities | -39.56M | -38.43M | -54.34M | -37.62M |
| ChangeInWorkingCapital | -3.72M | 2.78M | -6.82M | 1.00M |
| ChangeInOtherCurrentLiabilities | -1.22M | -1.15M | -907.00K | -1.73M |
| ChangeInOtherCurrentAssets | -2.02M | 0.00 | ||
| ChangeInPayablesAndAccruedExpense | -2.08M | 3.34M | -3.88M | 4.96M |
| ChangeInPayable | -3.88M | 4.96M | ||
| ChangeInAccountPayable | -3.88M | 4.96M | ||
| ChangeInPrepaidAssets | 139.00K | 405.00K | -2.28M | -2.05M |
| ChangeInReceivables | -555.00K | 181.00K | 249.00K | -181.00K |
| ChangesInAccountReceivables | -555.00K | 181.00K | 249.00K | -181.00K |
| OtherNonCashItems | 1.43M | 1.00M | 1.82M | -26.00K |
| StockBasedCompensation | 5.93M | 6.00M | 6.75M | 5.28M |
| AmortizationOfSecurities | -16.00K | -1.06M | 351.00K | 1.40M |
| DepreciationAmortizationDepletion | 203.00K | 255.00K | 233.00K | 158.00K |
| DepreciationAndAmortization | 203.00K | 255.00K | 233.00K | 158.00K |
| OperatingGainsLosses | -890.00K | |||
| GainLossOnSaleOfPPE | 0.00 | |||
| NetIncomeFromContinuingOperations | -43.39M | -47.41M | -56.67M | -45.44M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CRIS
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|